PD 156707

Known as: PD-156707 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1995-2011
012319952011

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
It is assumed that the regulation of cardiac endothelin (ET) receptor density is abnormal in heart diseases. From that… (More)
Is this relevant?
2002
2002
Endothelin-1 (ET-1) is considered an intermediary in the constrictor response of the pulmonary vasculature to hypoxia and, by… (More)
  • table 1
  • figure 2
  • figure 4
  • table 2
  • table 3
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Recent studies implicate reactive oxygen species (ROS) such as superoxide anions and H(2)O(2) in the proliferation of systemic… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2001
2001
Clinically significant increases in pulmonary vascular resistance have been noted on acute withdrawal of inhaled nitric oxide (NO… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
Is this relevant?
Review
1998
Review
1998
PD 156707 is a highly potent, selective antagonist of the ETA receptor that has demonstrated efficacy in a number of different… (More)
Is this relevant?
1997
1997
The objective of this study was to determine the in vivo effectiveness of the selective endothelin ETA receptor antagonist PD… (More)
Is this relevant?
1996
1996
A sensitive and selective liquid chromatographic assay for determining the non-peptide endothelin A receptor antagonist PD 156707… (More)
Is this relevant?
1996
1996
Episodes of myocardial ischemia are associated with increases in cardiac venous plasma endothelin (ET) concentrations, suggesting… (More)
Is this relevant?
1996
1996
We have proposed that ischemic preconditioning in rabbit hearts is initiated by adenosine receptor stimulation resulting in… (More)
Is this relevant?
1995
1995
We describe the pharmacological characteristics of PD 156707 (sodium 2-benzo[1,3]dioxol-5-yl-4-(4-methoxy-phenyl)-4-oxo-3-(3,4,5… (More)
Is this relevant?